Telomir Pharmaceuticals, Inc. completed its acquisition of TELI Pharmaceuticals, Inc. on 2026-04-22, according to the Form 8-K Telomir Pharmaceuticals, Inc. filed with the SEC on 2026-04-24. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Telomir Pharmaceuticals, Inc. |
|---|---|
| Acquired | TELI Pharmaceuticals, Inc. |
| Completed | 2026-04-22 |
| Reported by | Telomir Pharmaceuticals, Inc. (TELO), the buyer |
| Filing | Form 8-K, filed 2026-04-24 |
Want the whole picture on Telomir Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Telomir Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Telomir Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On April 22, 2026, Telomir Pharmaceuticals, Inc. (the "Company") completed its acquisition of TELI Pharmaceuticals, Inc. ("TELI") pursuant to the previously announced merger agreement (the "Transaction").
More from the filing
The information contained in Item 1.01 above is incorporated herein. .
Entry into a Material Definitive Agreement On April 22, 2026, Telomir Pharmaceuticals, Inc. (the "Company") completed its acquisition of TELI Pharmaceuticals, Inc. ("TELI") pursuant to the previously announced merger agreement (the "Transaction").
The Transaction was previously approved by the Company's shareholders during the Company's annual shareholders meeting on March 23, 2026.
Quoted from Telomir Pharmaceuticals, Inc.'s Form 8-K.
This is the only completed acquisition Telomir Pharmaceuticals, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Telomir Pharmaceuticals, Inc.Look up Telomir Pharmaceuticals, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.